<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21216197</PMID><DateCompleted><Year>2011</Year><Month>03</Month><Day>01</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-4465</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>2</Issue><PubDate><Year>2011</Year><Month>Feb</Month></PubDate></JournalIssue><Title>The Lancet. Neurology</Title><ISOAbbreviation>Lancet Neurol</ISOAbbreviation></Journal><ArticleTitle>Efficacy and safety of dutasteride in patients with spinal and bulbar muscular atrophy: a randomised placebo-controlled trial.</ArticleTitle><Pagination><StartPage>140</StartPage><EndPage>147</EndPage><MedlinePgn>140-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1474-4422(10)70321-5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Spinal and bulbar muscular atrophy (SBMA) is caused by polyglutamine expansion in the androgen receptor, which results in ligand-dependent toxicity. Animal models have a neuromuscular deficit that is mitigated by androgen-reducing treatment. We aimed to assess the efficacy and safety of the 5&#x3b1;-reductase inhibitor dutasteride in patients with SBMA, and to identify outcome measures for use in future studies of the disease.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We undertook a randomised, double-blind, placebo-controlled, single-site clinical trial in ambulatory, symptomatic men with genetically confirmed SBMA. Participants were assigned by random number table to receive dutasteride (0&#xb7;5 mg per day) or placebo orally for 24 months. Patients and investigators were masked to treatment allocation. The primary outcome measure was quantitative muscle assessment (QMA). The final efficacy analysis included all patients who were compliant with study treatment at 24 months. This trial was registered with ClinicalTrials.gov, NCT00303446.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">50 men were randomly assigned to treatment groups (25 dutasteride, 25 placebo), and 44 were included in the efficacy analysis (21 dutasteride, 23 placebo). At 24 months, the placebo group showed a decrease of 4&#xb7;5% (-0&#xb7;30 kg/kg) from baseline in weight-scaled muscle strength as indicated by QMA, and the dutasteride group had an increase in strength of 1&#xb7;3% (0&#xb7;14 kg/kg); the difference between groups (5&#xb7;8%, 95% CI -5&#xb7;9 to 17&#xb7;6; p=0&#xb7;28) was not significant. Prespecified secondary outcome measures of creatine kinase, muscle strength and function, motor nerve conduction, activities of daily living, and erectile function did not show a significant difference between the study groups in change from baseline. Quality of life, as measured by the physical component summary of the Medical Outcomes Study 36-item Short Form version 2, favoured dutasteride (change in score from baseline: placebo, -3&#xb7;6%, vs dutasteride, 2&#xb7;1%; p=0&#xb7;01), whereas the mental component summary favoured placebo (3&#xb7;3%vs -3&#xb7;2%; p=0&#xb7;03). The dutasteride group had fewer patients reporting falls than did the placebo group (9 vs 16; p=0&#xb7;048); there were no other significant differences in reported adverse events.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Our study did not show a significant effect of dutasteride on the progression of muscle weakness in SBMA, although there were secondary indications of both positive and negative effects compared with placebo. A longer trial duration or larger number of patients might be needed to show an effect on disease progression. Performance testing, QMA, and quality of life measures were identified as potentially useful endpoints for future therapeutic trials.</AbstractText><CopyrightInformation>Copyright &#xc2;&#xa9; 2011 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fern&#xe1;ndez-Rhodes</LastName><ForeName>Lindsay E</ForeName><Initials>LE</Initials><AffiliationInfo><Affiliation>Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kokkinis</LastName><ForeName>Angela D</ForeName><Initials>AD</Initials></Author><Author ValidYN="Y"><LastName>White</LastName><ForeName>Michelle J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Watts</LastName><ForeName>Charlotte A</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Auh</LastName><ForeName>Sungyoung</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Jeffries</LastName><ForeName>Neal O</ForeName><Initials>NO</Initials></Author><Author ValidYN="Y"><LastName>Shrader</LastName><ForeName>Joseph A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Lehky</LastName><ForeName>Tanya J</ForeName><Initials>TJ</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Li</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Ryder</LastName><ForeName>Jennifer E</ForeName><Initials>JE</Initials></Author><Author ValidYN="Y"><LastName>Levy</LastName><ForeName>Ellen W</ForeName><Initials>EW</Initials></Author><Author ValidYN="Y"><LastName>Solomon</LastName><ForeName>Beth I</ForeName><Initials>BI</Initials></Author><Author ValidYN="Y"><LastName>Harris-Love</LastName><ForeName>Michael O</ForeName><Initials>MO</Initials></Author><Author ValidYN="Y"><LastName>La Pean</LastName><ForeName>Alison</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Schindler</LastName><ForeName>Alice B</ForeName><Initials>AB</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Cheunju</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Di Prospero</LastName><ForeName>Nicholas A</ForeName><Initials>NA</Initials></Author><Author ValidYN="Y"><LastName>Fischbeck</LastName><ForeName>Kenneth H</ForeName><Initials>KH</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00303446</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>Z01 NS003037-01</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>Z01 NS003037-02</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>ZIA NS003037-03</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>ZIA NS003037-04</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>01</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Neurol</MedlineTA><NlmUniqueID>101139309</NlmUniqueID><ISSNLinking>1474-4422</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001378">Azasteroids</NameOfSubstance></Chemical><Chemical><RegistryNumber>O0J6XJN02I</RegistryNumber><NameOfSubstance UI="D000068538">Dutasteride</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Neurol. 2011 Feb;10(2):113-5</RefSource><PMID Version="1">21216198</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000058" MajorTopicYN="N">Accidental Falls</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001378" MajorTopicYN="N">Azasteroids</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055534" MajorTopicYN="N">Bulbo-Spinal Atrophy, X-Linked</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068538" MajorTopicYN="N">Dutasteride</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050723" MajorTopicYN="N">Fractures, Bone</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflicts of interest</b>. ADK owns stock in GlaxoSmithKline, Inc.. MJW&#x2019;s stipend was paid by a fellowship from the NIH Clinical Research Training Program, which is supported in part by funds paid to the NIH Foundation by Pfizer, Inc.. NADP is currently employed by and receives stock options from Johnson &amp; Johnson. KHF serves as an unpaid member of advisory boards for Biogen Idec and Prosensa.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>3</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21216197</ArticleId><ArticleId IdType="mid">NIHMS267238</ArticleId><ArticleId IdType="pmc">PMC3056353</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(10)70321-5</ArticleId><ArticleId IdType="pii">S1474-4422(10)70321-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chahin N, Klein C, Mandrekar J, Sorenson E. Natural history of spinal-bulbar muscular atrophy. Neurology. 2008;70:1967&#x2013;1971.</Citation><ArticleIdList><ArticleId IdType="pubmed">18490617</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejager S, Bry-Gauillard H, Bruckert E, et al. A comprehensive endocrine description of Kennedy's disease revealing androgen insensitivity linked to CAG repeat length. J Clin Endocrinol Metab. 2002;87:3893&#x2013;3901.</Citation><ArticleIdList><ArticleId IdType="pubmed">12161529</ArticleId></ArticleIdList></Reference><Reference><Citation>Adachi H, Waza M, Katsuno M, et al. Pathogenesis and molecular targeted therapy of spinal and bulbar muscular atrophy. Neuropathol Appl Neurobiol. 2007;33:135&#x2013;151.</Citation><ArticleIdList><ArticleId IdType="pubmed">17359355</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuno M, Adachi H, Kume A, et al. Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron. 2002;35:843&#x2013;854.</Citation><ArticleIdList><ArticleId IdType="pubmed">12372280</ArticleId></ArticleIdList></Reference><Reference><Citation>Banno H, Katsuno M, Suzuki K, et al. Phase 2 trial of leuprorelin in patients with spinal and bulbar muscular atrophy. Ann Neurol. 2009;65:140&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pubmed">19259967</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuno M, Banno H, Suzuki K, et al. Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9:875&#x2013;884.</Citation><ArticleIdList><ArticleId IdType="pubmed">20691641</ArticleId></ArticleIdList></Reference><Reference><Citation>Tindall DJ, Rittmaster RS. The rationale for inhibiting 5&#x3b1;-reductase isoenzymes in the prevention and treatment of prostate cancer. J Urol. 2008;179:1235&#x2013;1242.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2667246</ArticleId><ArticleId IdType="pubmed">18280514</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhodes LE, Freeman BK, Auh S, et al. Clinical features of spinal and bulbar muscular atrophy. Brain. 2009;132:3242&#x2013;3251.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2792370</ArticleId><ArticleId IdType="pubmed">19846582</ArticleId></ArticleIdList></Reference><Reference><Citation>Hislop HJ, Montgomery J, Connelly B, Daniels L. Daniels and Worthingham's muscle testing: techniques of manual examination. 6th ed. Philadelphia: W.B: Saunders; 1995.</Citation></Reference><Reference><Citation>Harris-Love M, Joe G, Abbett K, Koziol D. Performance-based assessment of functional limitation and muscle endurance: Reliability of the adult myositis assessment tool. J Neurol Phys Ther. 2004;28:179&#x2013;180.</Citation></Reference><Reference><Citation>Takeuchi Y, Katsuno M, Banno H, et al. Walking capacity evaluated by the 6-minute walk test in spinal and bulbar muscular atrophy. Muscle Nerve. 2008;38:964&#x2013;971.</Citation><ArticleIdList><ArticleId IdType="pubmed">18642379</ArticleId></ArticleIdList></Reference><Reference><Citation>Light KE, Behrman AL, Thigpen M, Triggs WJ. The 2-minute walk test: A tool for evaluating walking endurance in clients with Parkinson's disease. Neurol Rep. 1997;21:136&#x2013;139.</Citation></Reference><Reference><Citation>Lynch DR, Farmer JM, Tsou AY, et al. Measuring Friedreich ataxia: complementary features of examination and performance measures. Neurology. 2006;66:1711&#x2013;1716.</Citation><ArticleIdList><ArticleId IdType="pubmed">16769945</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen RC, Cappelleri JC, Gendrano N., 3rd The International Index of Erectile Function (IIEF): a state-of-the-science review. Int J Impot Res. 2002;14:226&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pubmed">12152111</ArticleId></ArticleIdList></Reference><Reference><Citation>Liveson JA, Ma DM. Laboratory reference for clinical neurophysiology. New York, NY: Oxford University Press; 1992.</Citation></Reference><Reference><Citation>Shefner JM, Cudkowicz ME, Zhang H, Schoenfeld D, Jillapalli D. The use of statistical MUNE in a multicenter clinical trial. Muscle Nerve. 2004;30:463&#x2013;469.</Citation><ArticleIdList><ArticleId IdType="pubmed">15316983</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehky TJ, Chen CJ, di Prospero NA, et al. Standard and modified statistical MUNE evaluations in spinal-bulbar muscular atrophy. Muscle Nerve. 2009;40:809&#x2013;814.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2763967</ArticleId><ArticleId IdType="pubmed">19670325</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JF, Koski A, Johnson LC. Spirometric standards for healthy nonsmoking adults. Am Rev Respir Dis. 1971;103:57&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">5540840</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleiss J. The design and analysis of clinical experiments. Chichester, UK: John Wiley and Sons; 1999.</Citation></Reference><Reference><Citation>National Health and Nutrition Examination Survey (NHANES) Hyattsville, MD, USA: 2005&#x2013;2006. National Center for Health Statistics.   http://www.cdc.gov/nchs/nhanes/nhanes2005-2006/nhanes05_06.htm.</Citation></Reference><Reference><Citation>Takeyama K-I, Ito S, Yamamoto A, et al. Androgen-dependent neurodegeneration by polyglutamine-expanded human androgen receptor in Drosophila. Neuron. 2002;35:855&#x2013;864.</Citation><ArticleIdList><ArticleId IdType="pubmed">12372281</ArticleId></ArticleIdList></Reference><Reference><Citation>Chevalier-Larsen ES, O'Brien CJ, Wang H, et al. Castration restores function and neurofilament alterations of aged symptomatic males in a transgenic mouse model of spinal and bulbar muscular atrophy. J Neurosci. 2004;24:4778&#x2013;4786.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729468</ArticleId><ArticleId IdType="pubmed">15152038</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt BJ, Greenberg CR, Allingham-Hawkins DJ, Spriggs EL. Expression of X-linked bulbospinal muscular atrophy (Kennedy disease) in two homozygous women. Neurology. 2002;59:770&#x2013;772.</Citation><ArticleIdList><ArticleId IdType="pubmed">12221177</ArticleId></ArticleIdList></Reference><Reference><Citation>Sar M, Stumpf WE. Androgen concentration in motor neurons of cranial nerves and spinal cord. Science. 1977;197:77&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">867053</ArticleId></ArticleIdList></Reference><Reference><Citation>Thigpen AE, Silver RI, Guileyardo JM, et al. Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression. J Clin Invest. 1993;92:903&#x2013;910.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC294929</ArticleId><ArticleId IdType="pubmed">7688765</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayhew JE, Florence JM, Mayhew TP, et al. Reliable surrogate outcome measures in multicenter clinical trials of Duchenne muscular dystrophy. Muscle Nerve. 2007;35:36&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">16969838</ArticleId></ArticleIdList></Reference><Reference><Citation>Barkin J, Roehrborn CG, Siami P, et al. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trial. BJU Int. 2009;103:919&#x2013;926.</Citation><ArticleIdList><ArticleId IdType="pubmed">19239460</ArticleId></ArticleIdList></Reference><Reference><Citation>Tokui K, Adachi H, Waza M, et al. 17-DMAG ameliorates polyglutamine-mediated motor neuron degeneration through well-preserved proteasome function in an SBMA model mouse. Hum Mol Genet. 2009;18:898&#x2013;910.</Citation><ArticleIdList><ArticleId IdType="pubmed">19066230</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Z, Chang Y-J, Yu IC, et al. ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptor. Nat Med. 2007;13:348&#x2013;353.</Citation><ArticleIdList><ArticleId IdType="pubmed">17334372</ArticleId></ArticleIdList></Reference><Reference><Citation>Palazzolo I, Stack C, Kong L, et al. Overexpression of IGF-1 in muscle attenuates disease in a mouse model of spinal and bulbar muscular atrophy. Neuron. 2009;63:316&#x2013;328.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2735765</ArticleId><ArticleId IdType="pubmed">19679072</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>